REG - Oxford Biomedica PLC - Business Update

Oxford BioMedicaAnnouncement

07/12/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231207:nRSG9533Va&default-theme=true

RNS Number : 9533V  Oxford Biomedica PLC  07 December 2023

 

 

 

Business Update

-    Current contracted value signed in 2023 of £124 million, an increase
of 47% compared to £85 million in the year ending 31 December 2022 (excluding
COVID-19 vaccine manufacturing)

-     On track to achieve 2023 guidance provided at the Interim Results and
reiteration of medium term guidance; growth supported by new orders recently
signed across lentivirus, adeno-associated virus (AAV) and adenoviral vectors

-   Progress towards multi-vector multi-site model with transfer of
lentiviral vector capabilities to Bedford, Massachusetts site and acquisition
of ABL Europe

-       Recruitment of UK and US Site Heads with extensive CDMO
experience to support move to site-based structure and strategic shift to a
pure-play CDMO

-       Significant progress in streamlining of operations to become a
pure-play CDMO resulting in annualised cost-savings of c.£30 million

 

Oxford, UK - 7 December 2023: Oxford Biomedica plc (LSE:OXB) ("Oxford
Biomedica" or "the Company"), a quality and innovation-led cell and gene
therapy CDMO, today announces a business update for the year ending 31
December 2023.

 

Becoming a pure-play CDMO in cell and gene therapy

Oxford Biomedica has made significant progress in its streamlining of
operations to become a pure-play quality and innovation-led global cell and
gene therapy CDMO. The Company has concluded the reorganisation of its
workforce, which, among other measures to increase efficiencies, includes a
more streamlined structure across the UK and US. This organisational
restructuring is tailored to boost efficiency and client-centricity, aligning
roles and operations with the specific requirements of a pure-play CDMO. These
strategic changes will result in a reduction of the ongoing cost base from 1
January 2024 by c.£30 million on an annualised basis compared to 2023.

 

Positive momentum in commercial activity

The Company continues to demonstrate robust business development activity, a
testament to its strong position in the viral vector space. This year, Oxford
Biomedica has more than doubled the number of contracts and client orders
signed compared to the previous year, reflecting a growing demand for its
services from a diverse array of pharmaceutical and biotech clients. Current
contracted value of client orders signed in 2023 is £124 million, an increase
of 47% compared to £85 million in the year ending 31 December 2022 (excluding
COVID-19 vaccine manufacturing). Furthermore, the pipeline of opportunities
continues to progress as anticipated, not only in lentivirus, AAV, and
adenoviral vectors but also in other vector types. Work with these additional
vector types now account for more than 10% of the weighted pipeline.

 

Current trading and medium term guidance

In line with guidance provided at the Interim Results in September, the
Company is on track to deliver revenues for the year ending 31 December 2023
of approximately £90 million.

Also in line with guidance provided at the Interim Results, Operating EBITDA
loss for the second half of 2023 is on track to be approximately £10 million
better than the first half.

The Company also remains on track to deliver broadly breakeven Operating
EBITDA in 2024, bolstered by positive momentum in business development
activities and new orders recently secured across lentivirus, adenoviral
vectors and AAV, with both new and existing clients. This momentum will
further support the Company's medium term guidance of a three-year revenue
CAGR in excess of 30%, and at least a doubling of revenues by the end of 2026.

The above guidance excludes the financial impact of the acquisition of ABL
Europe SAS ("ABL Europe"). The Company will provide further financial guidance
after the completion of this transaction, currently expected in the first
quarter of 2024.

 

Multi viral vector CDMO capabilities across multiple sites

 

Oxford Biomedica has achieved significant progress in transferring its
lentiviral vector capabilities to its Bedford, Massachusetts site. The
transfer of its 5L process is already underway. This will be followed shortly
by the introduction of 7L scale and 50L pilot scale capabilities. The material
produced from these pilot scale batches will be instrumental in supporting
assay qualification for pre-clinical activities as well as for IND
(Investigational New Drug) and IMPD (Investigational Medicinal Product
Dossier) enabling studies.

 

In October 2023, Oxford Biomedica welcomed Thierry Cournez, formerly of Merck
Life Science, as Chief Operating Officer & Site Head of UK Operations, to
lead the integration of Oxford Biomedica's sites and take direct
responsibility for the Company's UK operations in Oxford. This appointment
follows the earlier recruitment of Mark Caswell who brings extensive CDMO
experience from his previous roles at Rentschler Biopharma and Lonza. In July
2023, he took on the role of Site Head of US Operations. The shift to a
site-based structure allows the Company to maximise efficiencies as well as be
better adapted to serve client's needs.

 

On 4 December 2023
(https://otp.investis.com/clients/uk/oxford_biomed1/rns/regulatory-story.aspx?cid=544&newsid=1739604)
, Oxford Biomedica announced it had entered into a sale and purchase agreement
with Institut Mérieux for the acquisition of ABL Europe for a consideration
of €15 million. This will support the future growth of all viral vector
segments and allow the Company to expand its international footprint into the
European Union with sites in Lyon and Strasbourg, France.

Completion of the transaction is currently expected to take place in the first
quarter of 2024 subject to the satisfaction and/or waiver of outstanding
conditions, including obtaining the necessary regulatory approvals.

 

Dr. Frank Mathias, Chief Executive Officer of Oxford Biomedica, commented:
"Oxford Biomedica is successfully delivering on its strategic vision to become
a pure-play CDMO. The streamlining of our operations has involved a strategic
shift towards a CDMO mindset and we are now focused on being entirely
client-centric. We remain encouraged by our increase in client orders, which
have doubled since 2022 and we are now well-positioned to drive robust revenue
growth while targeting broadly breakeven Operating EBITDA by the end of 2024."

 

Attendance at the Annual J.P. Morgan Healthcare Conference

Oxford Biomedica is attending the Annual J.P. Morgan Healthcare
Conference. Frank Mathias, Chief Executive Officer, will give a presentation,
which will be available on the Oxford Biomedica website after the conference
at www.oxb.com/investors/results-reports-presentations-webcasts .

 

-Ends-

Enquiries:

 

Oxford Biomedica plc:

Sophia Bolhassan, VP, Corporate Affairs and IR

T: +44 (0) 7394 562 425 / E: ir@oxb.com

 

ICR Consilium:

Mary-Jane Elliott / Matthew Neal / Davide Salvi

T: +44 (0)20 3709 5700 / E: oxfordbiomedica@consilium-comms.com

 

About Oxford Biomedica

 

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene
therapy CDMO with a mission to enable its clients to deliver life changing
therapies to patients around the world.

 

One of the original pioneers in cell and gene therapy, the Company has more
than 25 years of experience in viral vectors; the driving force behind the
majority of gene therapies. The Company collaborates with some of the world's
most innovative pharmaceutical and biotechnology companies, providing viral
vector development and manufacturing expertise in lentivirus, adeno-associated
virus (AAV) and adenoviral vectors. Oxford Biomedica's world-class
capabilities span from early-stage development to commercialisation. These
capabilities are supported by robust quality-assurance systems, analytical
methods and depth of regulatory expertise.

 

Oxford Biomedica, a FTSE4Good constituent, is headquartered in Oxford, UK. It
has locations across Oxfordshire, UK and near Boston, MA, US. Learn more at
www.oxb.com (https://www.oxb.com/) , and follow us on LinkedIn
(https://www.linkedin.com/company/oxford-biomedica/) and YouTube
(https://www.youtube.com/user/OxfordBioMedica) .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDBQLLBXLLZFBQ